Results 101 to 110 of about 22,433 (204)

Naltrexone for Acute Management of Compulsive Sexual and Obsessive Symptoms in a Patient With a Neurodevelopmental Disorder. [PDF]

Case Rep Psychiatry
Constantin E, Deol MS, Yaun J, Singh H, Glass OM.   +4 more
europepmc   +1 more source

Treatment of opiate dependency : a multimodal model using naltrexone

, 2010
The portfolio examines use of opiate antagonist medication (naltrexone hydrochloride) as a safe and effective treatment for opiate dependence.
Ross. Colquhoun (13785940)
core  

Examining the Impact of Trial Length on Detecting Medication Effects for Alcohol Use Disorder: A Meta‐Regression Study

Alcohol, Clinical and Experimental Research, Volume 50, Issue 6, June 2026.
This study examined the association between trial length and observed medication effect sizes in pharmacotherapy randomized controlled trials (RCTs) for alcohol use disorder (AUD). Secondary meta‐regression analyses of 139 RCTs found no significant differences in observed effect sizes for abstinence‐ or drinking‐based endpoints between shorter (< 12 ...
Malia A. Belnap, Katie Witkiewitz, Joseph P. Schacht, Raymond F. Anton, Arnie P. Aldridge, Steven J. Nieto, Lara A. Ray   +6 more
wiley   +1 more source

The Use of Naltrexone to Successfully Treat Severe Hailey-Hailey Disease. [PDF]

Cureus
Mehrabian F, Vaughan E, Abid M, Gandhi N, Hawari R.   +4 more
europepmc   +1 more source

Emergency Departments Need to Train and Hire More Sub‐Specialists in Addiction Medicine

AEM Education and Training, Volume 10, Issue 3, June 2026.
Anthony Spadaro, Timothy Kelly, Jason Morris, Megan E. Heeney   +3 more
wiley   +1 more source

Assessing Major Adverse Liver Outcomes With Baclofen Compared to Acamprosate in Compensated Alcohol‐Associated Cirrhosis

Alimentary Pharmacology &Therapeutics, Volume 63, Issue 12, Page 1673-1684, June 2026.
We conducted a nationwide, multicenter cohort study using a target trial emulation framework to compare baclofen and acamprosate in patients with compensated alcohol‐associated cirrhosis. After matching, baclofen initiation was associated with a higher 1‐year risk of major adverse liver outcomes, driven primarily by hepatic encephalopathy, particularly
Yee Hui Yeo, Sepideh Mehravar, Ellen Choi, Ju Dong Yang, Hyun‐Seok Kim, Yun Wang, Aarshi Vipani, Hirsh D. Trivedi, Walid Ayoub, Parnian Naji, Alexander Kuo, Chun‐Ying Wu, Lorenzo Leggio, Juan Pablo Arab   +13 more
wiley   +1 more source

The expanding potential of low-dose naltrexone in clinical practice with a focus on long COVID. [PDF]

Ment Health Clin
Pucci SL, Veide A, Pierce H, Kaminski D.
europepmc   +1 more source

Obesity Treatments and Weight Changes in Clinical Practice After Discontinuation of Semaglutide or Tirzepatide

Diabetes, Obesity and Metabolism, Volume 28, Issue 6, Page 4795-4805, June 2026.
ABSTRACT Aims To describe obesity treatments in real‐world settings after discontinuation of semaglutide or tirzepatide and variability in weight change post‐discontinuation. Materials and Methods This retrospective cohort study used electronic health records from 1 January 2021, to 30 June 2025, in a large health system in Ohio and Florida.
Hamlet Gasoyan, Rebecca Schulte, Christopher B. Boyer, Nicholas J. Casacchia, W. Scott Butsch, Phuc Le, Ali Aminian, Marcio L. Griebeler, Bartolome Burguera, Michael B. Rothberg   +9 more
wiley   +1 more source

Effects of long-term sustained naltrexone release on the optic center in opioid-dependent patients Case-control study in four provinces of China

, 2011
Very little is known about visual functional recovery following long-term naltrexone administration in opioid-dependent patients. In the present study, a portable event-related potential (ERP) working system was utilized to collect and record ERP in ...
Yu, Longchuan, Wang, Dongmei, Jia, SW (reprint author), Hong Kong Univ Sci & Technol, Shenzhen Peking Univ, Med Ctr, Shenzhen 518036, Guangdong, Peoples R China., Chen, Qing, Hu, Shu, He, Shengxi, Jia, Shaowei   +6 more
core  

Lower Risk of Cardiovascular Events in Patients With Clinical Atherosclerotic Cardiovascular Disease Who Initiated Semaglutide 2.4 mg in the Real‐World: Results From the SCORE—Clinical ASCVD Study

Diabetes, Obesity and Metabolism, Volume 28, Issue 6, Page 4975-4990, June 2026.
ABSTRACT Aims To evaluate the association between semaglutide 2.4 mg and major adverse cardiovascular events (MACE) among adults with clinical atherosclerotic cardiovascular disease (ASCVD) and overweight/obesity without diabetes in real‐world clinical practice.
Michael G. Nanna, Carlos Mena‐Hurtado, Victoria Divino, Zhenxiang Zhao, Yan Chen, Joanna Boland, Jinlin Song, Andrea Traina, Kerem Ozer, Filip K. Knop, Kim G. Smolderen   +10 more
wiley   +1 more source